Eva-Maria Willing, Claudia Vollbrecht, Christine Vössing, Peggy Weist, Simon Schallenberg, Johanna M Herbst, Stefanie Schatz, Balázs Jóri, Guillaume Bataillon, Philipp Harter, Vanda Salutari, Antonio Gonzáles Martin, Ignace Vergote, Nicoletta Colombo, Julia Roeper, Tobias Berg, Regina Berger, Bettina Kah, Trine Jakobi Noettrup, Markus Falk, Kathrin Arndt, Andreas Polten, Isabelle Ray-Coquard, Franziska Selzam, Judith Pirngruber, Stefanie Schmidt, Michael Hummel, Markus Tiemann, David Horst, Jalid Sehouli, Eric Pujade-Lauraine, Katharina Tiemann, Elena Ioana Braicu, Lukas C Heukamp
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine detection of driver mutations in homologous recombination repair (HRR) genes and genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay and an associated bioinformatic pipeline that fulfils our institution's specific needs...
June 30, 2023: Cancers